Publicaciones en las que colabora con JULIO MORATINOS ARECES (28)

2011

  1. Differential sensitivity to adrenergic stimulation underlies the sexual dimorphism in the development of diabetes caused by Irs-2 deficiency

    Biochemical Pharmacology, Vol. 81, Núm. 2, pp. 279-288

2008

  1. Adipocytokines: Implications in the prognosis and drug treatment of cardiovascular diseases

    Revista Clinica Espanola, Vol. 208, Núm. 5, pp. 239-246

  2. Fármacos antidiabéticos. Insulinas y antidiabéticos orales

    Velázquez. Farmacología Básica y Clínica (Editorial Médica Panamericana), pp. 621-643

2007

  1. Disregulation in sympathetic activity explains gender differences in irs-2knockout mice

    Fundamental & Clinical Pharmacology

  2. Oral insulin-mimetic compounds that act independently of insulin

    Diabetes, Vol. 56, Núm. 2, pp. 486-493

2006

  1. The imidazoline I2-site ligands BU 224 and 2-BFI inhibit MAO-A and MAO-B activities, hydrogen peroxide production, and lipolysis in rodent and human adipocytes

    European Journal of Pharmacology, Vol. 552, Núm. 1-3, pp. 20-30

2005

  1. Methylamine but not mafenide mimics insulin-like activity of the semicarbazide-sensitive amine oxidase-substrate benzylamine on glucose tolerance and on human adipocyte metabolism

    Pharmacological Research, Vol. 52, Núm. 6, pp. 475-484

2004

  1. Benzylamine exhibits insulin-like effects on glucose disposal, glucose transport and fat cell lipolysis in rabbits and diabetic mice

    Fundamental & Clinical Pharmacology

  2. Benzylamine exhibits insulin-like effects on glucose disposal, glucose transport, and fat cell lipolysis in rabbits and diabetic mice

    Journal of Pharmacology and Experimental Therapeutics, Vol. 309, Núm. 3, pp. 1020-1028

  3. Defects in insulin secretion and lipolysis display gender-differences inthe IRS-2 knockout model

    Fundamental & Clinical Pharmacology

  4. Fármacos antidiabéticos. Insulinas y antidiabéticos orales

    Velázquez. Farmacología Básica y Clínica (Editorial Médica Panamericana S.A.), pp. 621-643

2003

  1. Ras-GRF1 signaling is required for normal β-cell development and glucose homeostasis

    EMBO Journal, Vol. 22, Núm. 12, pp. 3039-3049

2002

  1. Role of μ-opioid receptors in insulin release in the presence of inhibitory and excitatory secretagogues

    European Journal of Pharmacology, Vol. 448, Núm. 1, pp. 95-104

2001

  1. Effects of verapamil and elgodipine on isoprenaline-induced metabolic responses in rabbits

    European Journal of Pharmacology, Vol. 415, Núm. 1, pp. 105-115

  2. Ligands for I2-imidazoline receptors induce insulin secretion in the rabbit

    Fundamental & Clinical Pharmacology

  3. Role of opioid receptors on the insulin inhibitory effect induced by a2-adrenoceptor stimulation

    Fundamental & Clinical Pharmacology

1999

  1. Role of niflumic acid on insulin secretion incuded by excitatory and inhibitory agonists in mouse pancreatic islets

    Diabetologia: Clinical, Translational and Experimental Diabetes and Metabolism

1998

  1. Role of α2-adrenoceptors on the hyperglycaemic and insulin secretory effects derived from α1- and β-adrenoceptor stimulation in the rabbit

    Journal of Autonomic Pharmacology, Vol. 18, Núm. 5, pp. 287-295

1997

  1. Comparative effects of calcium channel blockers and indomethacin on insulin secretion and blood pressure increase derived from α1-adrenoceptor stimulation in the rabbit

    Journal of Autonomic Pharmacology, Vol. 17, Núm. 5, pp. 293-302

1993

  1. Coexistence of β2‐ and β3‐adrenoceptors in plasma potassium control in conscious rabbits

    Journal of Autonomic Pharmacology, Vol. 13, Núm. 3, pp. 227-236